Headlands Research Inc.
05/13/2026 | Press release | Distributed by Public on 05/13/2026 10:01
Coadministration of mRNA-1345 RSV vaccine with high-dose quadrivalent influenza vaccine in adults aged 65 and older
Jack Vu, MD, Principal Investigator at Headlands Artemis Institute-Riverside, co-authored a new paper reporting results from a phase 3 study evaluating the coadministration of the mRNA-1345 RSV vaccine (mRESVIA) with a high-dose seasonal influenza vaccine in adults aged 65+.
The study found that coadministration was generally well tolerated, produced strong immune responses against influenza strains, and supported maintained protection against RSV-related lower respiratory tract disease. These findings help support more convenient vaccination strategies for older adults and may improve vaccine uptake during the respiratory virus season.
Read more about the findings in Human Vaccines & Immunotherapeutics.
Headlands Research Inc. published this content on May 13, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 13, 2026 at 16:01 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]